Neoplasms
1,112
126
174
634
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
217 trials with published results (20%)
Research Maturity
634 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.0%
133 terminated out of 1112 trials
82.7%
-3.9% vs benchmark
6%
69 trials in Phase 3/4
34%
217 of 634 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 634 completed trials
Clinical Trials (1112)
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC)
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Data Collection, Clinical Care and Interventions in CCR, NCI
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
Ready for Safe Cancer Treatment (RESET): A Comprehensive Perioperative Program for Surgical Oncology
Anticoagulation in Patients With Venous Thromboembolism and Cancer
Vorasidenib Expanded Access Program
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors